分子标记物表达预测乳腺癌蒽环类新辅助化疗疗效价值研究  

Expression of molecular markers predict breast cancer to neoadjuvant anthracycline chemotherapy value

作　　者：陈毅作[1,2] 陈灿铭[1] 费菲[1] 张家新[1] 陆劲松[1] 狄根红[1] 柳光宇[1] 杨文涛[3] 陆洪芬[3] 沈镇宙[2,1] 邵志敏[1] 吴炅 

机构地区：[1]复旦大学附属肿瘤医院乳腺外科,上海200032 [2]温州医学院附属第一医院肿瘤外科,浙江温州325000 [3]复旦大学附属肿瘤医院病理科,上海200032

出　　处：《中国实用外科杂志》2011年第10期941-943,共3页Chinese Journal of Practical Surgery

摘　　要：目的探讨局部晚期乳腺癌病人肿瘤组织分子生物学标记物的表达及其与新辅助化疗有效率的关系。方法采用免疫组化的方法检测2000年1月至2010年12月复旦大学附属肿瘤医院乳腺外科收治的420例乳腺癌新辅助化疗病人化疗术后标本中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)/neu、p53、Cathepsin-D、p27、cyclinD1、Bax、Ki67、TOPOII、GSTπ、MDR和Bcl-2等分子标记物的表达情况,分析这些分子标记物的表达与新辅助化疗疗效之间的关系。结果 p53或cathepsin-D或GSTπ阴性的病人化疗疗效要显著优于阳性的病人,多因素回归分析提示GSTπ和p53是独立的新辅助化疗疗效预测指标。结论 GSTπ和p53可作为判定乳腺癌蒽环类新辅助化疗方案敏感性的两个独立预测指标。Objective To investigate the predictive value of biological markers for responsiveness to anthracyline-based regimen in neoadjuvant systemic therapy for local advanced breast caner. Methods Postoperative paraffin-embedded tumor samples from 420 breast cancer patients admitted between January 2000 and December 2010 in Department of Breast.Surgery of Fudafl University Shanghai Cancer Center were examined for expression of ER, PR, Her-2/neu and other 15 markers by immunohistochemistry, to analyze the predictive value of the biological markers for response to neoadjuvant chemotherapy. Results Negative p53, cathepsin-D and loss of GSTπ were significantly predictive for an effective response to anthracycline-based neoadjuvant chemotherapy. In multivariate logistic regression analysis, the GSTπ and p53 status were found with independent predictive value. Conclusion Loss of GSTπ and p53 independently predict the response to anthracycline-based regimen.

关 键 词：乳腺癌 新辅助化疗 预测因子 免疫组织化学 

分 类 号：R6[医药卫生—外科学]